Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma closed its previously announced underwritten offering, raising US$50 million in gross proceeds through the sale of 10,309,280 common shares at a price of US$4.85 per share. Cantor and Barclays acted as joint bookrunning managers, while Bloom Burton Securities Inc. and Lucid Capital Markets served as lead managers, with the company paying a total cash commission of US$3 million.
Key figures
- Deal Value Usd
- 50000000
- Offering Price
- 4.85
- Shares Offered
- 10309280
- Underwriter commission
- 3000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.